Loading...
Loading...
Ultomiris, the successor to Alexion Pharmaceuticals Inc's ALXN paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year.
- The drug posted $701 million in sales during 1H of 2021, Alexion said in a recent securities filing, a whopping 48% increase over the same period in 2020.
- After debuting with approval in adult PNH in late 2018, Ultomiris joined the blockbuster club in 2020 with $1.08 billion in sales.
- The older Soliris continued to deliver and posted first-half sales of $2.1 billion, a 5% Y/Y increase.
- Overall revenues turned out to about $3.33 billion for the first half, a 15% increase over the $2.89 billion a year ago.
- Recently, Alexion announced topline results from Ultomiris Phase 3 study evaluating Ultomiris in generalized myasthenia.
- Price Action: ALXN shares are up 1.34 at $181.85 during the market session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in